Consensus Treatment Guidelines and Recommendations to Treat Hepatitis-C Infected Populations

Abstract

Unlike other infectious diseases and viral infections, the long-term chronicity of hepatitis C infection could worsen or propagate to irreversible extra hepatic manifestations like decompensated cirrhosis or the development of hepatocellular carcinoma. The recent real-world clinical data of hepatitis C patients treated with IFN-free DAAs are still fewer to conclude or decide the best treatment protocols and guidelines for those who are still awaiting the treatment. However; based on the clinical data retrieved from the diverse patient cohorts, multicenter and multinational clinical studies, and pre- and post-therapeutic monitoring of hepatitis C treated patients enable the clinicians, physicians, and health care providers to sketch consensus treatment guidelines and recommendations for the safe administration of DAAs in general and vulnerable hepatitis C infected populations. Interestingly and luckily, the treatment guidelines and recommendations approved by the FDA and CDC are following and working well in real-world clinical, hospital, and primary health care centers to manage hepatitis C, infected individuals. Albeit; for certain special populations like pediatric and pregnant hepatitis C females, we do not have clear guidelines for DAAs usage and their therapeutic monitoring. Furthermore, certain DAAs are not recommended in decompensated cirrhotics, in HCV rebound patients, and in previous treatment failure with a DAAs regimen. In this book chapter, we enlist updated treatment guidelines and recommendations to treat general as well as special hepatitis C-infected populations with DAAs and will briefly portray an overview of the pros and cons of these recommendations in real-world clinical settings.<br>